A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Intravenous Dose Study of a novel TREM2 agonist (VGL101) in Healthy Volunteers (HVs)

VGL-101 - Vigil Neuro

Seala (VG101) - Bionovo

https://www.aan.com/MSA/Public/Events/AbstractDetails/52817

Andreas Meier; Spyridon Papapetropoulos, MD, PhD; David Stiles, PhD; Ryan O'Mara, Other; Rajasimhan Rajagovindan, PhD; Andrew James Marsh; Kelly Neelon, PhD; Evan A. Thackaberry, PhD

Mar 12, 2023